The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study

Ann Rheum Dis. 2011 Jul;70(7):1340-1. doi: 10.1136/ard.2010.137935. Epub 2010 Nov 10.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interleukin-2 Receptor alpha Subunit / antagonists & inhibitors
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins / therapeutic use*
  • Scleroderma, Diffuse / drug therapy*
  • Skin / pathology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • IL2RA protein, human
  • Immunosuppressive Agents
  • Interleukin-2 Receptor alpha Subunit
  • Recombinant Fusion Proteins
  • Basiliximab